

# Stanford

---

## Peter Du

Ph.D. Student in Cancer Biology, admitted Summer 2020

### Publications

---

#### PUBLICATIONS

- **Temporal genomic analysis of melanoma rejection identifies regulators of tumor immune evasion.** *bioRxiv : the preprint server for biology*  
Cohen Shufel, S., Pai, J. A., Cao, Y., Pal, L. R., Levy, R., Yao, W., Cheng, K., Zemanek, M., Bartok, O., Weller, C., Yin, Y., Du, P. P., Yakubovich, et al  
2023
- **Glioma synapses recruit mechanisms of adaptive plasticity.** *Nature*  
Taylor, K. R., Barron, T., Hui, A., Spitzer, A., Yalcin, B., Ivec, A. E., Geraghty, A. C., Hartmann, G. G., Arzt, M., Gillespie, S. M., Kim, Y. S., Maleki Jahan, S., Zhang, et al  
2023
- **Targeting TBK1 to overcome resistance to cancer immunotherapy.** *Nature*  
Sun, Y., Revach, O. Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G., Kim, S., Fu, A., Ma, X., Gwee, et al  
2023; 615 (7950): 158-167
- **GLIOMA SYNAPSES RECRUIT MECHANISMS OF ADAPTIVE PLASTICITY**  
Taylor, K., Barron, T., Zhang, H., Hui, A., Hartmann, G., Ni, L., Venkatesh, H., Du, P., Mancusi, R., Yalcin, B., Chau, I., Ponnuswami, A., Aziz-Bose, et al  
OXFORD UNIV PRESS INC. 2022: 25
- **Systematic discovery of recombinases for efficient integration of large DNA sequences into the human genome.** *Nature biotechnology*  
Durrant, M. G., Fanton, A., Tycko, J., Hinks, M., Chandrasekaran, S. S., Perry, N. T., Schaepe, J., Du, P. P., Lotfy, P., Bassik, M. C., Bintu, L., Bhatt, A. S., Hsu, et al  
2022
- **In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.** *Nature immunology*  
Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., Wolfe, C. H., Wiesmann, F., Knudsen, et al  
2022
- **Pathogenic or benign?** *Nature biotechnology*  
Du, P. P., Liu, K., Bassik, M. C., Hess, G. T.  
2022
- **Checkpoint blockade-induced CD8+T cell differentiation in head and neck cancer responders** *JOURNAL FOR IMMUNOTHERAPY OF CANCER*  
Zhou, L., Zeng, Z., Egloff, A., Zhang, F., Guo, F., Campbell, K. M., Du, P., Fu, J., Zolkind, P., Ma, X., Zhang, Z., Zhang, Y., Wang, et al  
2022; 10 (1)
- **Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity** *NATURE*  
Griffin, G. K., Wu, J., Iracheta-Vellve, A., Patti, J. C., Hsu, J., Davis, T., Dele-Oni, D., Du, P. P., Halawi, A. G., Ishizuka, J. J., Kim, S. Y., Klaeger, S., Knudsen, et al  
2021; 595 (7866): 309-+
- **In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma** *IMMUNITY*  
Dubrot, J., Lane-Reticker, S., Kessler, E. A., Ayer, A., Mishra, G., Wolfe, C. H., Zimmer, M. D., Du, P. P., Mahapatra, A., Ockerman, K. M., Davis, T. R., Kohnle, I. C., Pope, et al  
2021; 54 (3): 571-+
- **Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade.** *Nature*

Ishizuka, J. J., Manguso, R. T., Cheruiyot, C. K., Bi, K. n., Panda, A. n., Iracheta-Vellve, A. n., Miller, B. C., Du, P. P., Yates, K. B., Dubrot, J. n., Buchumenski, I. n., Comstock, D. E., Brown, et al  
2019; 565 (7737): 43–48